Authors Posts by Joshua Rodriguez

Joshua Rodriguez

2430 POSTS 444 COMMENTS
Hey everyone, I'm Joshua Rodriguez. I'm the founder of CNA Finance as well as several other sites. If you'd like to connect with me, follow me on or Twitter! I'd love to see ya there. Also, if you're looking for top quality content for your blog, news outlet, or any other website for that matter, please reach out to me at Info@CNAFin.com! Legal Disclaimer - CNA Finance is NOT an investment advisor. All investment decisions should be well thought out and made with the help of a an investment advisor. For our full legal disclaimer, please scroll to the bottom right of this page.

0 242
FireEye Inc FEYE Stock News

FireEye Inc (NASDAQ: FEYE)

FireEye is having an incredibly strong day in the market today. At the opening bell, the stock was already trading on dramatic gains, leading to an alert from our partners at Trade Ideas. Since then, the stock hasn’t seen much movement, but has held onto strong gains. At the moment (1:29), FEYE is trading at $12.37 per share after a gain of $0.88 per share or 7.66% thus far today.





Goldman Sachs Upgrades FEYE

As mentioned above, Goldman Sachs has made the decision to upgrade FireEye, leading to big gains in the value of the stock. The firm upgraded the stock from a Sell rating to a Buy rating, also increasing its price target on the stock. The price target has been increased from $10.00 to $15.00. In a statement, Goldman Sachs analyst, Gabriela Borges had the following to offer…

Street 2017 product revenue and billings estimates have been materially reset, with mix shift to recurring revenue occurring faster than we expected, and increased detail on the pricing model for Helix. We believe the introduction of Helix, an advanced analytics platform, addresses many of FireEye’s previous challenges by reducing total cost of ownership (TCO) by 33-50%, and streaming the company’s go-to-market under its new head of sales. As the new model comes into focus, we expect more consistent execution and FCF generation. Since being added to Americas Sell List on 11/22/16, FEYE is -12% vs. S&P 500 =7%.”




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on FEYE. In particular, we’re interested in watching as the company launches Helix to see just how beneficial the new product is to the books. Nonetheless, we’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Max Pixel]

Tripadvisor Inc Common Stock TRIP Stock News

Tripadvisor Inc Common Stock (NASDAQ: TRIP)

Tripadvisor was off to a relatively normal day in the market today. That is, until minutes ago when the stock spiked in a big way, prompting our partners at Trade Ideas to send an alert about the growth. The gains seem to be the result of a rumor that’s surfacing. Nonetheless, the stock is trading at $42.20 per share after a gain of $0.80 per share or 1.93%.





PCLN Rumored To Be Taking TRIP Over

As mentioned above, Tripadvisor was having a relatively normal day in the market until a rumor broke just minutes ago, causing rocket-like upward movement. The rumor that broke is that Priceline may be acquiring the company relatively soon. However, we do not believe that there is any validity to the rumors.




While TRIP and PCLN would definitely sync up well together, the rumor just doesn’t seem to hold weight. There is no suggestion of what the price might be, nor has there been any reports of interest in this deal from either company as of late. This is the first we’re hearing of it, and the source is social media, making it nearly impossible to pin down the original source. All in all, things just aren’t adding up.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TRIP. In particular, we’re interested in learning more about the potential takeover by PCLN. Of course, we don’t believe that there’s any validity to the rumor, but we can’t see into the future. So, anything could happen. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 214
SuperValu Inc. SVU Stock News

SuperValu Inc. (NYSE: SVU)

SuperValu is having an incredibly strong day in the market today. At the open, the stock was already trading in the green and has only climbed from there. Ultimately, the cause of the gains is an upgrade. As soon as the upgrade happened, the stock started spiking upward, causing our partners at Trade Ideas to alert us of the gains. At the moment (12:01), SVU is trading at $3.73 per share after a gain of $0.39 per share or 11.68% thus far today.





SVU Upgraded By RBC

As mentioned above, SuperValu is having an incredibly strong day in the market today as the result of an upgrade. The upgrade came from RBC Capital, who made the decision to increase the rating on the stock from a Sector Perform to an Outperform. Of course, the upgrade let to a frenzy among investors, causing the stock to fly.




What Do You Think?

Where do you think SVU is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

LSC Communications Inc LKSD Stock News

LSC Communications Inc (NYSE: LKSD)

LSC Communications is having an incredibly strong day in the market, which is interesting as they just announced a secondary offering. Nonetheless, the secondary caused excitement, sending the stock up and prompting our partners at Trade Ideas to alert us of the gains. At the moment (11:32), LKSD is trading at $23.49 per share after a gain of $2.66 per share or 12.77% thus far today.





LKSD Announces Secondary Offering

As mentioned above, LSC Communications is having an incredibly interesting start to the day today after announcing a secondary offering. The company said it would be selling 6,242,082 shares of common stock at a price of $20.25 per share. The company also informed investors that it has given underwirters at 30-day option to purchase up to an additional 936,420 shares at the secondary pricing.




The interesting part in all of this is that the stock is actually climbing. In general, secondary offerings cause concerns with regard to dilution, leading to declines in the stock’s value, but that’s not the case with LKSD. This shows that the market sees a need for the money and expects that the funds raised through the offering will lead to stronger operations and better results. While this is a rarity in the market, it’s always nice to see.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on LKSD. In particular, we’re interested in learning more about the company’s plans with the money it is raising, and watching the company put the plan into action. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 583
Flexion Therapeutics Inc FLXN Stock News

Flexion Therapeutics Inc (NASDAQ: FLXN) | Sanofi SA (ADR) (NYSE: SNY)

Flexion Therapeutics is having an overwhelmingly strong start to the trading session today. After FiercePharma made an announcement that the company is nearing a deal with Sanofi, the stock spiked in a big way, prompting our partners at Trade Ideas to alert us to the movement. At the moment (10:30), FLXN is trading at $24.67 per share after a gain of $4.99 per share (25.36%) thus far today.





FLXN Nears $1 Billion Deal With SNY

As mentioned above, Flexion Therapeutics is having an overwhelmingly strong start to the trading session as reports break that the company is close to closing a $1 billion deal with Sanofi. According to a source close to the story, Sanofi is considering purchasing the company and the deal is close.




According to the release, the price on the acquisition, if it happens, will come in the range of the mid-30’s per share. This makes sense, as FLXN has a knee injection product for osteoarthritis that would fit well with SNY’s biosurgery division, which also markets an osteoarthritis injectable. Nonetheless, this report has been unconfirmed. While it looks like there’s definitely validity to this one, it’s important to treat the story as a rumor until confirmation comes.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching to see if FLXN is acquired by SNY. While we are treating this as a rumor at the moment, there’s a much stronger probability of an acquisition actually happening than we see with most rumors. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Update 11:02: SNY refuses to comment on FLXN takeover rumor.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 295
Vascular Biogenics Ltd VBLT Stock News

Vascular Biogenics Ltd (NASDAQ: VBLT)

Vascular Biogenics is having a great start to the trading session today, and for good reason. The company released overwhelmingly positive results from a recent Phase II clinical study. As a result, the stock started to climb dramatically, causing our partners at Trade Ideas to alert us of the gains. Currently (10:13), VBLT is trading at $5.25 per share after a gain of $0.75 per share or 16.67% thus far today.





VBLT Releases Positive Phase II Data

As mentioned above, Vascular Biogenics is having a strong morning in the market today as the result of positive data from a recent Phase II trial. The trial was designed around VB-111, an experimental treatment designed for patients with advanced, differentiated thyroid cancer.




According to the release, the primary endpoint was met. The data showed that 47% of patients in the therapeutic dose cohort achieved PFS-6, compared to 25% in the sub-therapeutic cohort. Both groups in the study met the primary endpoint of 25% PFS response at 6 months or 25% PFS-6.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be following VBLT incredibly closely. In particular, we’re interested in following the company’s ongoing work surrounding VB-111 as the treatment seems to be doing well in clinical studies. Nonetheless, we’ll continue to follow the story closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Max Pixel]

0 255
Nantkwest Inc NK Stock News

Nantkwest Inc (NASDAQ: NK)

Nantkwest is off to an incredibly strong start in the trading session today, and for good reason. The company just achieved orphan drug designation, leading to excitement among investors. As a result, the stock spiked upward, prompting our partners at Trade Ideas to alert us of the gains. At the moment (10:01), NK is trading at $3.54 per share after a gain of $0.11 per share or 3.15% thus far today.





NK Receives Orphan Drug Designation

As always, as soon as we received the alert, informing us of the gains on Nantkwest, the CNA Finance team went to work to see why the stock was gaining. Ultimately, the gains are the result of the company’s newly realized Orphan Drug Designation from the US FDA. The Orphan Drug Designation has been granted for the experimental treatment known as Ganitumab, which is being tested as a treatment for Ewing Sarcoma.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to follow the NK story incredibly closely. In particular, we’re interested in the company’s ongoing work with regard to Ganitumab, especially now considering the orphan drug designation. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

NVIDIA Corporation NVDA Stock News

NVIDIA Corporation (NASDAQ: NVDA)

NVIDIA Corporation is having a rough start to the session today after announcing demand issues and price cuts. At the opening bell, the stock was trading slightly in the red before jumping to the green. However, as soon as the price cut announcement hit, the stock went on a mad dash toward the bottom, prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:46), NVDA is trading at $107.42 per share after a loss of $0.65 per share (0.60%) thus far today.





NVDA Slashes Product Pricing

As mentioned above, NVIDIA Corporation is having a rough start to the day today after announcing that it has cut pricing. The company recently cut the price of its GTX 1080 graphics cards from $699 to $499 in hopes of increasing sales. The company said that the price cuts are the result of decreasing demand for the product, as motherboard players continue to see decreases in shipments in the first quarter; they are not expecting things to improve in the second quarter.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on NVDA. In particular, we’re interested in seeing if the price cuts result in increased sales or if this is a futile effort, as consumers are changing their computing habits. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 459
Insys Therapeutics Inc INSY tock News

Insys Therapeutics Inc (NASDAQ: INSY)

Insys Therapeutics is having an overwhelmingly strong beginning to the trading session today, starting the day off in the green. As a result, our partners at Trade Ideas sent an alert surrounding the stock, which prompted us to dig and see what was happening. The gains seem to be the result of the company’s new treatment being in the news due to a DEA ruling. At the moment (9:31), INSY is trading at $11.42 per share after a gain of $1.21 per share (11.86%) thus far today.





DEA Issues Ruling On INSY Syndros(TM)

As mentioned above, Insys Therapeutics is having an overwhelmingly strong start to the trading session today after its treatment came up in a DEA ruling. In an announcement, the US Drug Enforcement Agency announced that it issued an interim final rule on Syndros(TM). The DEA has scheduled the treatment as a Schedule II controlled substance under the Controlled Substances Act. This is great news, as the marijuana-derived treatment has been scheduled as a safer drug than marijuana itself. In a statement, Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO and CMO at INSY, had the following to offer:




Insys is looking forward to bringing this new drug product to chemotherapy patients to help alleviate their nausea and vomiting and AIDS patients with anorexia associated weight loss, respectively. We look forward to interacting with the FDA to finalize labeling and subsequent launch of Syndros in the second half of 2017.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on INSY. In particular, we’ll be following the ongoing work surrounding Syndros, and we are excited for the launch of the treatment later this year. We’ll continue to follow the story closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

Ford Motor Company F Stock News

Ford Motor Company (NYSE: F)

Ford was already having a rough time in the pre-market. However, minutes ago, our partners at Trade Ideas informed us that the stock was taking a bit of a dive. As soon as they did, we started digging to see why, and learned that the company has made the decision to slash guidance for Q1 earnings per share. At the moment (9:15), $F is trading at $11.48 per share after a loss of $0.29 per share (2.46%) thus far today.





$F Slashes Q1 EPS Guidance

As mentioned above, Ford Motor Company is taking a bit of a dive in the pre-market at the moment, and for good reason. The company announced that it has made the decision to cut guidance for the first quarter down quite a bit. In fact, $F has slashed guidance down to between $0.30 per share and $0.35 per share for first quarter earnings. Not only is this quite a bit lower than previous guidance, it is way off when we look at analyst estimates at $0.45 per share.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching $F incredibly closely. In particular, we’re interested in hearing why the company cut guidance, as this is still a breaking story and not many details are being offered. We’ll continue to follow the story closely and bring the news as it breaks!

Update 12:01: We’re starting to see some big activity here. 18 million shares just traded at $11.77.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 3674
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...